Cassava Sciences, Inc. (SAVA)

$ 77
10.65 (+16.05%)
-
Symbol SAVA
Price $ 77
Beta 1.174
Volume Avg. 1.89M
Market Cap 3.08B
Shares () -
52 Week Range 2.28-117.54
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -11.79% Sell
ROA -4.37% Neutral
Operating Margin -
Debt / Equity 1.02% Neutral
P/E -
P/B 10.33 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Why Cassava Sciences Was Up 15% in May

Why Cassava Sciences Was Up 15% in May

Thanks to key funding, its Alzheimer's drug is on track even after Biogen's historic approval. ...

The Motley Fool
Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment

Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment

Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment. ...

Seeking Alpha
Are Options Traders Betting on a Big Move in Cassava Sciences (SAVA) Stock?

Are Options Traders Betting on a Big Move in Cassava Sciences (SAVA) Stock?

Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately. ...

Zacks Investment Research
Annovis' Alzheimer's Drug Is Interesting, Cassava's Looks Better

Annovis' Alzheimer's Drug Is Interesting, Cassava's Looks Better

Annovis Bio tripled Friday after reporting exciting Alzheimer's data. Its drug posiphen is not clearing plaques or flooding receptors, but inhibits amyloid-β precursor protein from translating toxic Aβ. ...

Seeking Alpha
Cassava Sciences to Participate in Q&A Panel Discussion on Alzheimer's Disease

Cassava Sciences to Participate in Q&A Panel Discussion on Alzheimer's Disease

- Virtual Panel to be Held on Wednesday, May 26 th , 11:00am Eastern Time - ...

GlobeNewsWire
Long-Term Small Molecule Studies Bode Well For Cassava Sciences' Alzheimer's Data

Long-Term Small Molecule Studies Bode Well For Cassava Sciences' Alzheimer's Data

The only effective Alzheimer's treatment on the market is aricept, but its effect falls off after six months because it simply floods receptors. ...

Seeking Alpha
Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development

Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development

Caladrius Biosciences Inc (NASDAQ: CLBS) has received $1.4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority. The Program ... ...

Benzinga
Cassava Sciences Announces New $2.7 Million Research Grant Award from National Institutes of Health

Cassava Sciences Announces New $2.7 Million Research Grant Award from National Institutes of Health

- Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Phase 3 Program with Simufilam - - Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Phase 3 Program with Simufilam - ...

GlobeNewsWire
Buying Cassava Sciences Ahead Of July Data

Buying Cassava Sciences Ahead Of July Data

The stock is off >70% from February high after going up 3x after the interim Alzheimer's data. Targeting $70 by the second interim data release in July (70% upside potential). ...

Seeking Alpha
Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer's disease

Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer's disease

- Randomized, Controlled Study is Designed to Evaluate Cognition  in Patients Who Continue Versus Discontinue Simufilam Over Six Months – ...

GlobeNewsWire

About


Mr. Remi Barbier
Healthcare
Biotechnology
Nasdaq Capital Market

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.